Core Viewpoint - GLP-1 agonists, such as semaglutide and tirzepatide, are popular weight loss medications, but a significant number of users discontinue their use within a year due to various factors, including cost, side effects, and prescription limitations [5][7]. Group 1: Impact of Discontinuation - A study indicated that approximately two-thirds of individuals who started using GLP-1 agonists in the U.S. stopped within a year [5]. - Upon discontinuation, many individuals experience weight regain, with studies showing that those who switched to a placebo regained nearly 7% of their weight after 11 months [12]. - An observational study found that 44% of individuals who stopped semaglutide regained at least 25% of their weight within a year [12]. Group 2: Health Risks Associated with Weight Regain - Discontinuation of semaglutide not only leads to weight regain but also a resurgence of health risks, including increased blood pressure, blood sugar, and cholesterol levels [13]. - Abdominal fat, which is linked to metabolic issues like heart disease and insulin resistance, tends to rebound after stopping the medication [13]. Group 3: Recommendations for Discontinuation - Gradual tapering off the medication rather than abrupt cessation may help mitigate rebound hunger and weight gain [14]. - Continuous monitoring of appetite and weight is advised for those who choose to stop the medication [14]. - Lifestyle changes, including diet and exercise, should be maintained even after discontinuation to help manage weight [15]. Group 4: Optimal Dosing Strategies - Research presented at the European Obesity Congress indicated that starting patients on the lowest effective dose of semaglutide and only increasing it when necessary can lead to significant weight loss while minimizing side effects [17]. - In a study, participants lost an average of 14.9 kg over 76 weeks while maintaining a low dose of semaglutide [17]. Group 5: Efficacy of Lower Doses - Another study demonstrated that a weekly dose of 0.5 mg of semaglutide resulted in an approximate 11% weight loss among participants [19].